High Approved
Abaloparatide Osteoporosis, fracture risk, bone-building therapy
FDA-approved human drug
Tap for details
Pathway / target
PTHrP analogue
Human availability
Yes — prescription use
Body areas
Bone remodeling system calcium metabolism skeleton
Research availability
Extensive human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Strong anabolic osteoporosis therapy, similar quiz lane to teriparatide.
Risks / limits
Hypercalcemia, dizziness/orthostasis, injection burden.
2024–2026 signal
Useful to distinguish bone-anabolic peptides from cosmetic/body-composition marketing peptides.
Hide details Very low Educational
Adipotide Fat loss, “targeted” adipose reduction, obesity
Not FDA-approved for human use
Tap for details
Pathway / target
Adipose vasculature-targeting peptidomimetic
Human availability
No — preclinical concept only
Aliases
Adipotide CKGGRAKDC-GG-(D)(KLAKLAK)2
Body areas
White adipose tissue vasculature kidney safety signals in primates
Research availability
Preclinical primate obesity study; no legitimate human-use pathway
WADA relevance
Could be athlete-problematic if used for body composition
Well-established
The key supportive data are preclinical, including non-human primate work; this is not a real consumer therapeutic.
Risks / limits
Renal toxicity signals in animal work, no human approval or routine human trial pathway.
2024–2026 signal
Should be treated as a preclinical obesity concept, not as a peptide option for humans.
Hide details High Approved
Afamelanotide Erythropoietic protoporphyria phototoxicity prevention
FDA-approved human drug
Tap for details
Pathway / target
Alpha-MSH analogue / melanocortin pathway
Human availability
Yes — specialty use
Body areas
Skin melanogenesis photoprotection pathways
Research availability
Strong but rare-disease-specific human evidence
WADA relevance
Usually not a sports-doping issue
Well-established
Effective in a rare-disease photoprotection context; not a cosmetic tanning peptide.
Risks / limits
Hyperpigmentation and implant/procedural considerations; narrow indication.
2024–2026 signal
Useful for drawing a hard line between legitimate melanocortin medicine and unapproved tanning peptides.
Hide details Very low Educational
AOD-9604 Fat loss/body recomposition
Not FDA-approved for human use
Tap for details
Pathway / target
GH fragment marketed for fat loss
Human availability
No — do not market for human use
Aliases
hGH fragment 176-191
Body areas
Adipose tissue GH-axis-adjacent metabolic signaling
Research availability
Some historical human studies; development did not establish a routine role
WADA relevance
Prohibited / athlete risk
Well-established
The marketed fat-loss story is much stronger than the evidence. It is not an approved obesity drug.
Risks / limits
FDA lists it as a safety-risk substance with limited safety-related information and reports of serious adverse events; athlete rules also matter.
2024–2026 signal
Important to route away from recommendation despite persistent fitness-market interest.
Hide details Low to moderate Educational
ARA-290 / Cibinetide Neuropathy, nerve repair, pain modulation
Investigational only
Tap for details
Pathway / target
Innate repair receptor (EPOR/CD131) agonist-like tissue-protective signaling
Human availability
No — not FDA-approved
Body areas
Peripheral nerves small fibers inflammatory signaling
Research availability
Limited human phase 2 neuropathy literature
WADA relevance
Usually not a sports-doping issue
Well-established
Small trials suggested symptom improvement in sarcoid-related small fiber neuropathy, but no approved product exists.
Risks / limits
Small evidence base, no FDA-approved pathway, unclear generalizability outside niche neuropathy settings.
2024–2026 signal
Still investigational; not a mainstream clinical peptide despite recurring online claims.
Hide details Very low Educational
BPC-157 Injury recovery, tendon healing, gut healing, 'recovery stacking'
Not FDA-approved for human use
Tap for details
Pathway / target
Experimental healing peptide; mechanism not clinically validated
Human availability
No — do not market for human use
Aliases
Body Protection Compound 157; 'Wolverine peptide'
Body areas
Claims center on gut mucosa, tendon/ligament, muscle, skin, vessels, and inflammation pathways
Research availability
Very limited human data; mostly preclinical
WADA relevance
Prohibited / high-risk for athletes
Well-established
Animal/preclinical literature dominates. Human evidence remains sparse and inadequate for routine clinical use.
Risks / limits
FDA says safety information is limited; purity/immunogenicity concerns; no established safe dose; athlete anti-doping risk.
2024–2026 signal
FDA lists BPC-157 among substances that may present significant safety risks in compounding, and USADA says it is prohibited and not approved for human clinical use. Tiny recent human signals do not change the regulatory status.
Hide details Moderate Approved
Bremelanotide Hypoactive sexual desire disorder discussions
FDA-approved human drug
Tap for details
Pathway / target
Melanocortin receptor agonist
Human availability
Yes — prescription use
Body areas
Central nervous system sexual desire circuitry blood pressure/autonomic system skin pigmentation
Research availability
Human evidence established but narrower than metabolic peptides
WADA relevance
Usually not a sports-doping issue
Well-established
Approved for acquired, generalized HSDD in premenopausal women; not a general libido enhancer for everyone.
Risks / limits
Nausea, transient BP rise, skin darkening/hyperpigmentation, limited indication.
2024–2026 signal
A useful example of a peptide where the approved indication is much narrower than the consumer marketing narrative.
Hide details Moderate Educational
Cagrilintide Obesity and appetite-control interest; amylin-pathway discussion
Investigational only
Tap for details
Pathway / target
Amylin receptor agonism
Human availability
No — trial use only
Aliases
Long-acting amylin analogue
Body areas
Brain satiety pathways stomach/gastric emptying pancreatic-metabolic axis
Research availability
Active late-stage human research
WADA relevance
Usually not a sports-doping issue
Well-established
Human studies support clinically meaningful weight loss, especially in combination approaches, but it is not FDA-approved.
Risks / limits
GI side effects and dose-tolerability issues; long-term real-world safety still pending.
2024–2026 signal
FDA states cagrilintide cannot be used in compounding under federal law; late-stage combo development with semaglutide continued through 2025–2026.
Hide details Moderate to high Educational
CagriSema Next-gen obesity and type 2 diabetes treatment interest
Investigational only
Tap for details
Pathway / target
Dual-pathway combo: amylin + GLP-1
Human availability
No — not approved as of Mar 2026
Aliases
Cagrilintide + semaglutide fixed combination
Body areas
Brain satiety circuits stomach pancreas liver adipose tissue
Research availability
Active phase 3 human trials / regulatory activity
WADA relevance
Usually not a sports-doping issue
Well-established
Late-stage trial results show strong weight-loss and glycemic effects, but the combo is still investigational.
Risks / limits
GI tolerability and eventual label/safety profile remain to be finalized.
2024–2026 signal
Phase 3 REDEFINE data appeared in 2025 and additional late-stage activity continued into 2026.
Hide details Low to moderate Educational
Cerebrolysin (peptide mixture) Memory, Alzheimer disease, stroke/TBI recovery, nootropic claims
Not FDA-approved for human use
Tap for details
Pathway / target
Porcine brain-derived peptide mixture with neurotrophic/noological claims
Human availability
No — not an FDA-approved U.S. product
Aliases
Cerebrolysin peptidergic nootropic mixture
Body areas
CNS cognition neurorecovery dementia/TBI discussions
Research availability
Human RCTs/meta-analyses outside normal U.S. practice
WADA relevance
Usually not a classic sports-doping issue
Well-established
There is a body of clinical literature, but evidence remains mixed and the product is not an FDA-approved U.S. therapeutic.
Risks / limits
Complex mixture rather than a single clean peptide, regulatory inconsistency, uncertain generalizability to gray-market sourcing.
2024–2026 signal
Good example of “some clinical data but not a legitimate U.S. peptide recommendation.”
Hide details Very low Educational
CJC-1295 Fat loss, muscle gain, anti-aging, GH 'stacking'
Not FDA-approved for human use
Tap for details
Pathway / target
GH-axis stimulation
Human availability
No — do not market for human use
Aliases
Long-acting GHRH analogue
Body areas
Hypothalamus/pituitary GH axis liver IGF-1 axis adipose tissue muscle bone
Research availability
Small human studies only; limited clinical data
WADA relevance
Prohibited / high-risk for athletes
Well-established
A few small human studies showed GH/IGF-1 effects, but there is no approved human-use role.
Risks / limits
FDA cites serious adverse events and limited clinical data; GH-axis peptides also carry anti-doping risk.
2024–2026 signal
FDA specifically lists CJC-1295 as a compounding safety-risk substance with serious adverse events reported.
Hide details Very low to low Educational
Delta sleep-inducing peptide (DSIP) Sleep, recovery, stress, withdrawal symptoms
Not FDA-approved for human use
Tap for details
Pathway / target
Uncertain neuropeptide signaling; historical sleep/endocrine investigations
Human availability
No — do not market for human use
Aliases
DSIP delta sleep-inducing peptide
Body areas
Sleep regulation CNS arousal stress-hormone studies
Research availability
Old small human studies; little modern regulated development
WADA relevance
Usually not a major sports-doping category, but athlete caution still warranted with any gray-market injectable
Well-established
The literature is old, small, and far from enough to support modern consumer peptide matching.
Risks / limits
Sparse modern safety data, uncertain mechanism, injection-market quality concerns.
2024–2026 signal
Still mainly a legacy/neuropeptide curiosity rather than a serious clinical peptide option.
Hide details Very low to low Educational
Dermorphin Analgesia, performance, pain control, obscure enhancement claims
Not FDA-approved for human use
Tap for details
Pathway / target
Potent mu-opioid receptor agonist peptide
Human availability
No — do not market for human use
Aliases
Dermorphin amphibian opioid peptide
Body areas
Pain pathways endocrine hormone release CNS
Research availability
Small human endocrine/analgesia studies + doping-detection literature
WADA relevance
Athlete issue; relevant to equine/human anti-doping surveillance
Well-established
It is a potent opioid peptide of research and anti-doping interest, not a legitimate current human therapeutic.
Risks / limits
Opioid-like adverse effects, legal/regulatory ambiguity, major quality-control risk outside formal research.
2024–2026 signal
Should sit firmly in the “educate only” bucket.
Hide details High Approved
Desmopressin Central diabetes insipidus, nocturia, some bleeding-disorder contexts
FDA-approved human drug
Tap for details
Pathway / target
Vasopressin V2 receptor agonist
Human availability
Yes — prescription use
Aliases
DDAVP Nocdurna Stimate
Body areas
Kidney collecting ducts water balance urinary system
Research availability
Extensive human literature
WADA relevance
Prohibited/TUE-relevant for athletes
Well-established
Very well established for water-balance disorders and select other uses.
Risks / limits
Hyponatremia/water intoxication is the key risk; requires careful selection and monitoring.
2024–2026 signal
Strong but narrow peptide; good example of a high-efficacy non-wellness peptide.
Hide details High Approved
Dulaglutide Type 2 diabetes and cardiometabolic risk reduction discussions
FDA-approved human drug
Tap for details
Pathway / target
GLP-1 receptor agonist
Human availability
Yes — prescription use
Body areas
Pancreas brain appetite circuits stomach cardiovascular system kidney-metabolic axis
Research availability
Extensive human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Well-established weekly GLP-1 RA for type 2 diabetes with cardiovascular-outcomes evidence; not the leading obesity-specific peptide in current practice.
Risks / limits
GI adverse effects, pancreatitis/gallbladder warnings, thyroid C-cell tumor boxed warning.
2024–2026 signal
Remains a strong diabetes peptide, but less central than semaglutide/tirzepatide for consumer obesity discovery flows.
Hide details Moderate to high Approved
Elamipretide / SS-31 Mitochondrial health, fatigue, endurance, rare-disease muscle weakness
FDA-approved human drug
Tap for details
Pathway / target
Mitochondrial cardiolipin binder
Human availability
Yes — prescription use for Barth syndrome only
Aliases
Forzinity SS-31 elamipretide
Body areas
Mitochondria skeletal muscle cardiac muscle cellular energy systems
Research availability
Human trials in mitochondrial disease; post-approval rare-disease use
WADA relevance
Usually not a sports-doping issue
Well-established
FDA accelerated approval exists for Barth syndrome; evidence should not be generalized to broad wellness or sports-performance claims.
Risks / limits
Narrow approved population, limited long-term real-world data, injection burden.
2024–2026 signal
Important change: 2025 FDA accelerated approval made SS-31/elamipretide a real human therapeutic rather than a pipeline-only peptide.
Hide details High Approved
Enfuvirtide Treatment-experienced HIV / salvage therapy
FDA-approved human drug
Tap for details
Pathway / target
HIV fusion inhibitor peptide
Human availability
Yes — prescription use
Body areas
Immune system HIV entry/fusion at CD4-target-cell interface
Research availability
Established human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Well established but now niche in modern HIV practice.
Risks / limits
Injection-site reactions, regimen complexity, infection-specific use only.
2024–2026 signal
Include if you want a truly broad peptide catalog; not relevant for consumer optimization.
Hide details Very low Educational
Epitalon Longevity, anti-aging, sleep, endocrine rejuvenation claims
Not FDA-approved for human use
Tap for details
Pathway / target
Experimental 'anti-aging' peptide
Human availability
No — do not market for human use
Body areas
Pineal/aging narrative cell senescence/telomere claims
Research availability
Mostly preclinical / speculative human-aging literature
WADA relevance
Usually not a sports-doping issue
Well-established
No accepted clinical evidence base supports the broad anti-aging claims made online.
Risks / limits
FDA says it has not identified safety-related information for the proposed routes of administration.
2024–2026 signal
Keep this in a red-zone longevity category: interesting hypothesis, not a supported consumer match.
Hide details High Approved
Eptifibatide Acute coronary syndrome / PCI contexts
FDA-approved human drug
Tap for details
Pathway / target
Platelet GP IIb/IIIa inhibitor peptide
Human availability
Yes — hospital use
Body areas
Platelets coronary circulation acute thrombosis pathway
Research availability
Established human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Well established as an antiplatelet peptide in acute cardiovascular care.
Risks / limits
Bleeding and thrombocytopenia; inpatient/acute-care use only.
2024–2026 signal
Medically important but not usually relevant to a self-improvement discovery quiz.
Hide details High Approved
Exenatide Type 2 diabetes and legacy GLP-1 comparison
FDA-approved human drug
Tap for details
Pathway / target
GLP-1 receptor agonist
Human availability
Yes — prescription use
Aliases
Byetta Bydureon BCise
Body areas
Pancreas stomach brain appetite circuits cardiovascular-metabolic system
Research availability
Older but extensive human literature
WADA relevance
Usually not a sports-doping issue
Well-established
An older GLP-1 RA with established glycemic benefit; not a leading modern obesity choice.
Risks / limits
GI adverse effects, injection burden, pancreatitis warning, renal caution.
2024–2026 signal
Important for historical completeness; generally eclipsed by newer once-weekly agents.
Hide details Early to moderate Educational
Follistatin / myostatin-axis agents Muscle gain, injury recovery, muscular dystrophy, physique enhancement
Investigational only
Tap for details
Pathway / target
Myostatin / activin signaling inhibition
Human availability
No — not FDA-approved
Aliases
Follistatin ACE-031 GDF-8 blockade myostatin inhibitor
Body areas
Skeletal muscle growth and repair endocrine growth signaling
Research availability
Preclinical + early human trial/gene-therapy literature
WADA relevance
Major athlete issue under growth-factor rules
Well-established
There is real research around myostatin inhibition and follistatin gene therapy, but gray-market vials are not established clinical products.
Risks / limits
Potential off-target growth effects, unknown long-term safety, athlete sanction risk, mismatch between research constructs and supplier vials.
2024–2026 signal
Still scientifically interesting, but not a legitimate self-use muscle-building peptide category.
Hide details Very low to low Educational
GHK-Cu (injectable peptide use) Skin/hair rejuvenation, wound repair, cosmetic interest
Not FDA-approved for human use
Tap for details
Pathway / target
Copper-binding signaling peptide
Human availability
No — injectable human use is not approved
Aliases
Copper peptide; note topical cosmetic use is a different category
Body areas
Skin wound healing hair follicles connective tissue
Research availability
Limited human data; topical/cosmetic literature exists separately
WADA relevance
Usually not a formal doping target, but quality/safety concerns dominate
Well-established
Topical cosmetic use is separate from injectable peptide-drug use. Injectable human evidence is limited.
Risks / limits
FDA notes limited human data for injectable routes; product quality and route-specific safety are major concerns.
2024–2026 signal
A 2026 topical wound trial interest exists, but this does not legitimize injectable clinic or self-use claims.
Hide details Very low Educational
GHRP-2 / GHRP-6 family Fat loss, muscle gain, recovery, GH-axis manipulation
Not FDA-approved for human use
Tap for details
Pathway / target
GH secretagogues / GH-releasing peptides
Human availability
No — do not market for human use
Aliases
Pralmorelin; examorelin/hexarelin-related GH-releasing peptides
Body areas
Pituitary GH axis liver IGF-1 axis glucose/cortisol regulation
Research availability
Small human studies; limited safety data
WADA relevance
Prohibited / high-risk for athletes
Well-established
The family has biologic activity, but there is no approved human-use role for the common wellness-market products.
Risks / limits
FDA cites serious adverse-event reports for GHRP-2 and safety concerns for GHRP-6, including glucose/cortisol issues.
2024–2026 signal
Good 'do not auto-match' family for any athlete or body-composition quiz branch.
Hide details Low to moderate Educational
Glutathione Skin brightening, “detox”, liver support, oxidative stress, neuropathy
Not FDA-approved for human use
Tap for details
Pathway / target
Endogenous tripeptide antioxidant / redox buffer
Human availability
No FDA-approved injectable peptide-drug pathway identified for wellness use
Aliases
Reduced glutathione GSH
Body areas
Liver detox/redox systems skin pigmentation claims nervous system oxidative stress
Research availability
Human trials exist in selected neurologic/oncology/hepatic contexts
WADA relevance
Usually not a sports-doping issue
Well-established
There is human research in selected disease settings, but common beauty/wellness injection claims are much more weakly supported.
Risks / limits
Route/formulation variability, weak support for many cosmetic claims, gray-market injection quality concerns.
2024–2026 signal
Useful to keep separate from peptide-hormone therapeutics because it is often marketed on beauty claims rather than robust FDA-approved indications.
Hide details High Approved
GnRH agonists Prostate cancer, endometriosis, fibroids, central precocious puberty, fertility protocol control
FDA-approved human drug
Tap for details
Pathway / target
Hypothalamic-pituitary-gonadal axis suppression
Human availability
Yes — prescription/clinic use
Aliases
Leuprolide goserelin triptorelin histrelin
Body areas
Hypothalamus/pituitary/gonads reproductive organs bone and metabolic axis
Research availability
Extensive human literature
WADA relevance
Athlete caution; several are prohibited/TUE-relevant
Well-established
Very well established in reproductive endocrinology and oncology, but not for lifestyle optimization.
Risks / limits
Hot-flash/low-sex-hormone symptoms, bone loss, mood/metabolic effects, fertility implications.
2024–2026 signal
A quiz can use this class only in diagnosis-driven pathways; not for body hacking.
Hide details High Approved
GnRH antagonists Prostate cancer and fertility/IVF protocol control
FDA-approved human drug
Tap for details
Pathway / target
Immediate gonadotropin suppression / IVF control
Human availability
Yes — prescription/clinic use
Aliases
Degarelix cetrorelix ganirelix
Body areas
Pituitary-gonadal axis reproductive organs
Research availability
Established human literature
WADA relevance
Athlete caution / possible TUE issues
Well-established
Well established for specific oncology and assisted-reproduction uses.
Risks / limits
Injection reactions, hypersensitivity, reproductive hormone suppression effects.
2024–2026 signal
Useful for fertility and oncology quiz branches, not for self-improvement flows.
Hide details Very low to low Educational
Hexarelin GH boosting, muscle gain, recovery, anti-aging
Not FDA-approved for human use
Tap for details
Pathway / target
GHS-R / ghrelin-receptor agonist; GH secretagogue
Human availability
No — do not market for human use
Aliases
Examorelin hexarelin acetate
Body areas
Pituitary GH axis downstream IGF-1 signaling prolactin/ACTH crossover
Research availability
Older human physiology studies; no modern approved pathway
WADA relevance
Major athlete issue; prohibited GH secretagogue
Well-established
It can stimulate GH in human studies, but there is no approved therapeutic pathway for current body-hacking uses.
Risks / limits
Hormonal off-target effects, contamination risk, athlete sanction risk, lack of modern efficacy/safety package.
2024–2026 signal
Remains mainly relevant to anti-doping and gray-market secretagogue discussions.
Hide details High Approved
Human chorionic gonadotropin (hCG) Fertility, testosterone recovery/PCT, weight loss claims
FDA-approved human drug
Tap for details
Pathway / target
LH receptor agonist / gonadotropin signaling
Human availability
Yes — prescription fertility/endocrine use
Aliases
Novarel Pregnyl chorionic gonadotropin
Body areas
Ovaries testes reproductive endocrine axis
Research availability
Extensive clinical use
WADA relevance
Major athlete issue; prohibited at all times in males
Well-established
Established fertility/endocrine uses; not an FDA-approved weight-loss drug.
Risks / limits
Gynecomastia or hormonal adverse effects, ovarian hyperstimulation risk, athlete sanction risk.
2024–2026 signal
USADA/WADA continue to flag hCG in male athletes; weight-loss marketing remains unsupported.
Hide details High Approved
Icatibant / ecallantide Acute hereditary angioedema attacks
FDA-approved human drug
Tap for details
Pathway / target
Bradykinin-pathway antagonism / kallikrein inhibition
Human availability
Yes — prescription use
Body areas
Vascular permeability skin GI tract airway/angioedema tissues
Research availability
Established human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Well established for acute hereditary angioedema treatment.
Risks / limits
Injection reactions; anaphylaxis risk for ecallantide; disease-specific use only.
2024–2026 signal
Important specialty peptide lane for swelling/angioedema diagnoses.
Hide details Very low to low Educational
IGF-1 analogs (Long R3 IGF-1 / DES-IGF-1) Muscle gain, recovery, injury repair, anabolic enhancement
Not FDA-approved for human use
Tap for details
Pathway / target
IGF-1 receptor agonism; anabolic growth-factor signaling
Human availability
No — black-market/bodybuilding availability does not equal legal human-use status
Aliases
IGF-1 LR3 Long R3 IGF-I IGF-DES DES(1-3) IGF-I
Body areas
Muscle connective tissue liver-growth signaling glucose metabolism
Research availability
Analytical anti-doping literature + older mechanistic biology; little or no legitimate therapeutic pathway
WADA relevance
Major athlete issue; prohibited growth-factor class
Well-established
These analogs are mainly relevant as performance-enhancement and anti-doping targets, not responsible consumer therapeutics.
Risks / limits
Anabolic/growth-factor safety uncertainty, hypoglycemia potential, athlete sanction risk, no approved human-use product.
2024–2026 signal
Still a prime example of “studied/abused/detectable” rather than legitimate human peptide therapy.
Hide details High Approved
Insulin Diabetes management, anabolic/bodybuilding misuse, glucose control
FDA-approved human drug
Tap for details
Pathway / target
Insulin receptor agonist
Human availability
Yes — established diabetes therapy
Aliases
Human insulin Humulin Novolin
Body areas
Pancreas-glucose axis liver muscle adipose tissue potassium handling
Research availability
Extensive human literature + decades of clinical use
WADA relevance
Athlete issue; prohibited without an appropriate TUE
Well-established
Essential therapy for type 1 diabetes and selected type 2 diabetes contexts; not a body-composition peptide.
Risks / limits
Severe hypoglycemia, coma, weight gain, acute medical emergencies from dosing errors.
2024–2026 signal
Anti-doping sensitivity remains high; this should never appear in a consumer self-improvement flow outside diagnosed diabetes care.
Hide details Very low Educational
Ipamorelin Fat loss, recovery, sleep/GH optimization, gut motility claims
Not FDA-approved for human use
Tap for details
Pathway / target
GH secretagogue
Human availability
No — do not market for human use
Aliases
GHS / ghrelin-receptor agonist
Body areas
Pituitary GH axis GI motility pathways liver IGF-1 axis adipose/muscle
Research availability
Small human studies only; limited safety data
WADA relevance
Prohibited / high-risk for athletes
Well-established
There is no approved human therapeutic role despite real biologic activity.
Risks / limits
FDA cites serious adverse events including death in one IV literature setting and inadequate safety information for proposed routes.
2024–2026 signal
Strong example of a peptide that is often sold as 'research' while lacking an FDA-approved human-use pathway.
Hide details Early to moderate Educational
Kisspeptin Fertility, IVF trigger, hypothalamic amenorrhea / reproductive-hormone interest
Investigational only
Tap for details
Pathway / target
Upstream reproductive-axis signaling (stimulates GnRH/LH/FSH)
Human availability
No — regulated research only
Aliases
Kisspeptin-54; kisspeptin-10 appears in gray-market compounding discussions
Body areas
Hypothalamus/pituitary/gonads reproductive hormones fertility axis
Research availability
Human fertility studies exist; still investigational
WADA relevance
Athlete caution if endocrine manipulation matters; not a typical consumer peptide
Well-established
Human proof-of-concept exists in fertility/reproductive endocrinology, but no FDA approval. FDA separately flags kisspeptin-10 as a compounding safety-risk substance due to limited safety information.
Risks / limits
Endocrine-axis perturbation, limited route-specific safety data, specialist-only context.
2024–2026 signal
2025 data included intranasal kisspeptin-54 rapidly stimulating gonadotropin release in humans.
Hide details Very low Educational
KPV / MGF / PEG-MGF Inflammation, gut healing, muscle repair/bodybuilding
Not FDA-approved for human use
Tap for details
Pathway / target
Miscellaneous early-stage anti-inflammatory and growth-factor-adjacent peptides
Human availability
No — do not market for human use
Aliases
KPV tripeptide; mechano growth factor; PEG-MGF
Body areas
KPV: gut/skin inflammation claims MGF/PEG-MGF: muscle/tendon repair, hypertrophy, and recovery claims
Research availability
Minimal or no identified human exposure data
WADA relevance
PEG-MGF is especially athlete-problematic
Well-established
These are too early or too poorly characterized for a responsible consumer match; native MGF and PEG-MGF are frequently sold into body-hacking markets without meaningful clinical validation.
Risks / limits
FDA says KPV lacks identified human exposure data and PEG-MGF lacks identified human exposure data and may pose immunogenicity risk; MGF/PEG-MGF concepts are also anti-doping sensitive.
2024–2026 signal
Both fit a 'do not auto-match' bucket for a serious quiz.
Hide details High Approved
Linaclotide IBS-C and chronic idiopathic constipation
FDA-approved human drug
Tap for details
Pathway / target
Guanylate cyclase-C agonist peptide
Human availability
Yes — prescription use
Body areas
Intestinal epithelium colon visceral pain signaling
Research availability
Established human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Well established for IBS-C/CIC symptom improvement.
Risks / limits
Diarrhea can be limiting; contraindicated in young children.
2024–2026 signal
Useful for a symptom-oriented GI quiz branch because it is a peptide with strong evidence but a very different goal profile from metabolic peptides.
Hide details High Approved
Liraglutide Weight management and type 2 diabetes, especially when older GLP-1 options are discussed
FDA-approved human drug
Tap for details
Pathway / target
GLP-1 receptor agonist
Human availability
Yes — prescription use
Body areas
Brain appetite circuits pancreas stomach liver adipose tissue cardiovascular system
Research availability
Extensive human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Well-established older GLP-1 RA for diabetes and weight management; generally less potent for weight loss than newer semaglutide/tirzepatide options.
Risks / limits
GI adverse effects, gallbladder disease, pancreatitis warning, thyroid C-cell tumor boxed warning, daily injections.
2024–2026 signal
Still clinically relevant, but newer incretins often displace it for weight-loss discussions because efficacy is lower.
Hide details Very low Educational
LL-37 Wound healing, antimicrobial, immune modulation
Not FDA-approved for human use
Tap for details
Pathway / target
Host-defense / antimicrobial peptide
Human availability
No — do not market for human use
Aliases
Cathelicidin LL-37
Body areas
Skin/wound bed immune system tumor biology concerns reproductive tissues
Research availability
Some human research; insufficient safety for marketed use
WADA relevance
Usually not a sports-doping issue
Well-established
Some real biology and limited human study history exist, but not enough to support routine human use.
Risks / limits
FDA says safety information is insufficient and notes nonclinical findings suggesting detrimental male-reproduction effects and protumorigenic potential in some tissues.
2024–2026 signal
Should be routed away from recommendation despite sounding scientifically sophisticated.
Hide details Moderate Educational
Mazdutide Obesity, liver fat reduction, diabetes, next-wave incretin interest
Investigational only
Tap for details
Pathway / target
Dual GLP-1 / glucagon receptor agonist
Human availability
No — not FDA-approved
Body areas
Brain appetite circuits pancreas liver adipose tissue GI-metabolic axis
Research availability
Phase 2/3 human obesity and diabetes studies
WADA relevance
Usually not a sports-doping issue
Well-established
Early human data suggest clinically relevant weight loss, but this remains a pipeline agent rather than an approved routine therapy.
Risks / limits
GI adverse effects, investigational uncertainty, no FDA-approved human-use pathway.
2024–2026 signal
2025 obesity data added credibility, but U.S. status is still investigational.
Hide details Very low Educational
Melanotan II Tanning, libido enhancement, body-image/cosmetic use
Not FDA-approved for human use
Tap for details
Pathway / target
Unapproved melanocortin analogue
Human availability
No — do not market for human use
Body areas
Skin pigmentation CNS sexual function pathways autonomic system
Research availability
Very limited human data; case reports and gray-market use
WADA relevance
Athlete caution; major safety concern regardless
Well-established
There is no approved human-use role. Small early studies do not justify commercial human use.
Risks / limits
FDA cites case reports of serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism.
2024–2026 signal
This should be an explicit red-zone peptide in any quiz.
Hide details High Approved
Metreleptin Generalized lipodystrophy and severe leptin deficiency states
FDA-approved human drug
Tap for details
Pathway / target
Leptin analogue
Human availability
Yes — prescription use for a rare disease
Body areas
Hypothalamic appetite signaling liver adipose tissue reproductive/endocrine metabolism
Research availability
Strong rare-disease human evidence
WADA relevance
Usually not a sports-doping issue
Well-established
Well established for congenital or acquired generalized lipodystrophy; not a general 'fat loss' peptide.
Risks / limits
Anti-drug antibodies, lymphoma warning context, specialist monitoring required.
2024–2026 signal
Important for a quiz because it distinguishes true rare-disease replacement therapy from consumer fat-loss marketing.
Hide details Very low Educational
MOTS-c Energy, metabolic health, insulin sensitivity, 'longevity' interest
Not FDA-approved for human use
Tap for details
Pathway / target
Experimental mitochondrial/metabolic peptide
Human availability
No — do not market for human use
Aliases
Mitochondrial-derived peptide
Body areas
Mitochondrial metabolism skeletal muscle liver adipose tissue
Research availability
Mostly preclinical; FDA notes no identified human exposure data
WADA relevance
Usually not a formal doping target, but quality/safety uncertainty is extreme
Well-established
Interesting biology, but human evidence is essentially absent for practical therapeutic use.
Risks / limits
FDA says it has not identified human exposure data and lacks important safety information.
2024–2026 signal
Good example of a trendy 'longevity' peptide that is still too early for consumer matching.
Hide details High Approved
Oxytocin Labor induction, postpartum hemorrhage, social bonding/anxiety claims
FDA-approved human drug
Tap for details
Pathway / target
Oxytocin receptor agonist
Human availability
Yes — clinician-supervised obstetric use
Aliases
Pitocin oxytocin acetate
Body areas
Uterus mammary glands hypothalamic-social signaling circuits
Research availability
Extensive clinical use; limited wellness-style human research
WADA relevance
Usually not a sports-doping issue
Well-established
Established obstetric drug; social/bonding or “wellness” uses are far less established.
Risks / limits
Uterine hyperstimulation, fetal distress, hypotension, hyponatremia/water intoxication.
2024–2026 signal
Still a hospital/obstetric drug, not a consumer self-improvement peptide.
Hide details Moderate Educational
Pemvidutide Obesity and MASLD/MASH interest
Investigational only
Tap for details
Pathway / target
GLP-1 / glucagon receptor agonist
Human availability
No — trial use only
Body areas
Brain appetite circuits liver fat/metabolism adipose tissue
Research availability
Active mid-stage human research
WADA relevance
Usually not a sports-doping issue
Well-established
Early-mid stage studies show weight-loss and liver-fat reductions, but the molecule is not approved.
Risks / limits
GI tolerability and full long-term risk profile remain under study.
2024–2026 signal
2025 data continued to support obesity/MASLD potential; ongoing studies remain phase 2 rather than established therapy.
Hide details Very low to low Educational
Pinealon / Thymalin family Anti-aging, cognition, immune support, longevity
Not FDA-approved for human use
Tap for details
Pathway / target
Short tissue-derived peptide bioregulators; mechanisms incompletely characterized
Human availability
No — do not market for human use
Aliases
Pinealon Thymalin bioregulatory peptides
Body areas
Immune signaling CNS/aging claims broad “bioregulation” framing
Research availability
Small regional human literature + mechanistic/preclinical work
WADA relevance
Usually not a central anti-doping category, but athlete caution still warranted
Well-established
Evidence is niche, heterogeneous, and not enough for responsible consumer matching.
Risks / limits
Limited independent replication, regional literature concentration, unclear regulatory status and product quality.
2024–2026 signal
Still largely a gray-market longevity niche rather than a mainstream clinically validated peptide category.
Hide details High Approved
Plecanatide IBS-C and chronic idiopathic constipation
FDA-approved human drug
Tap for details
Pathway / target
Guanylate cyclase-C agonist peptide
Human availability
Yes — prescription use
Body areas
Intestinal epithelium colon bowel fluid secretion
Research availability
Established human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Well established for constipation-predominant bowel disorders.
Risks / limits
Diarrhea is the main limiting adverse effect.
2024–2026 signal
A second strong GI peptide option for constipation-focused quiz flows.
Hide details Very low Educational
PNC-27 Cancer, cellular repair, highly speculative anti-aging claims
Not FDA-approved for human use
Tap for details
Pathway / target
p53/HDM-2-targeted cell-penetrating anticancer peptide concept
Human availability
No — preclinical / experimental only
Aliases
PNC27 p53-derived anticancer peptide
Body areas
Cancer-cell targeting concepts no validated normal consumer-use target organ
Research availability
Mainly preclinical and ex vivo cancer literature
WADA relevance
Usually not a mainstream anti-doping issue
Well-established
This is not a clinically established human peptide therapy; supportive data are preclinical or ex vivo.
Risks / limits
No approved product, no standard human therapeutic pathway, major mismatch between cancer-lab literature and retail peptide marketing.
2024–2026 signal
Best handled as a fringe research item rather than a quiz outcome option.
Hide details Moderate to high Approved
Pramlintide Post-prandial glucose control, appetite/satiety interest, amylin-pathway discussions
FDA-approved human drug
Tap for details
Pathway / target
Amylin analogue
Human availability
Yes — prescription use
Body areas
Brain satiety pathways stomach/gastric emptying pancreas-glucose axis
Research availability
Established human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Approved as an adjunct for insulin-treated diabetes; confirms that amylin biology is clinically meaningful in humans.
Risks / limits
Nausea, hypoglycemia risk when combined with insulin, added injection complexity.
2024–2026 signal
Renewed interest because newer amylin-based obesity candidates revived attention to the pathway.
Hide details Moderate to high Educational
Retatrutide Next-generation obesity, diabetes, and liver-fat interest
Investigational only
Tap for details
Pathway / target
Triple agonist: GLP-1/GIP/glucagon
Human availability
No — trial use only
Aliases
LY3437943; 'triple G' in media slang
Body areas
Brain appetite circuits pancreas liver adipose tissue metabolic rate/energy balance
Research availability
Active phase 3 human trials
WADA relevance
Usually not a sports-doping issue, but gray-market use is high risk
Well-established
Phase 2 obesity data showed very large weight loss; still investigational and not approved for any condition.
Risks / limits
GI effects, heart-rate/other metabolic tolerability questions, long-term safety still being defined; gray-market versions are especially risky.
2024–2026 signal
Still in phase 3 as of 2026. FDA says products containing retatrutide sold 'for research' or 'not for human consumption' are being warned against, and retatrutide cannot be used in compounding.
Hide details Very low Educational
Selank Anxiety relief, calm/focus, mood stabilization claims
Not FDA-approved for human use
Tap for details
Pathway / target
Experimental anxiolytic/neurotropic peptide
Human availability
No — not approved in the U.S.
Body areas
Central nervous system stress/anxiety pathways
Research availability
Limited human data; mostly small/older studies
WADA relevance
Usually not a sports-doping issue
Well-established
There is no FDA-approved human role and the evidence base is too thin for routine use.
Risks / limits
FDA says it lacks important safety information for selank acetate administered to humans.
2024–2026 signal
Use as an education-only item in any nootropics/mood branch.
Hide details High Approved
Semaglutide Obesity/overweight, type 2 diabetes, cardiometabolic risk, liver fat discussions
FDA-approved human drug
Tap for details
Pathway / target
GLP-1 receptor agonist
Human availability
Yes — prescription use
Aliases
Wegovy Ozempic Rybelsus
Body areas
Brain appetite circuits pancreas stomach liver adipose tissue cardiovascular system kidney
Research availability
Extensive human trials + real-world use
WADA relevance
Usually not a sports-doping issue
Well-established
Strong evidence for weight loss and glycemic control; molecule has U.S. approvals across diabetes/obesity, with added cardiovascular and kidney outcomes data.
Risks / limits
GI adverse effects, gallbladder disease, dehydration, pancreatitis warning, diabetic retinopathy caution, thyroid C-cell tumor boxed warning for relevant products.
2024–2026 signal
2024: Wegovy gained cardiovascular risk-reduction indication; 2025: Ozempic added CKD-related risk reduction in T2D; 2026 FDA labeling also references Wegovy tablets.
Hide details Very low Educational
Semax Focus, cognition, stroke/neuroprotection claims, mood resilience
Not FDA-approved for human use
Tap for details
Pathway / target
Experimental neurotropic peptide
Human availability
No — not approved in the U.S.
Aliases
Heptapeptide nootropic marketed in wellness circles
Body areas
Central nervous system stress/cognition pathways
Research availability
Mostly preclinical or limited regional human data
WADA relevance
Usually not a sports-doping issue
Well-established
There is no FDA-approved human role in the U.S.; evidence is too limited for broad recommendation.
Risks / limits
FDA says it has no or limited safety-related information for proposed compounded routes.
2024–2026 signal
A classic example of a 'smart peptide' with more online enthusiasm than robust translational evidence.
Hide details Low to moderate Educational
Sermorelin GH boosting, anti-aging, recovery, physique enhancement
Not FDA-approved for human use
Tap for details
Pathway / target
Growth hormone-releasing hormone analog
Human availability
No current FDA-approved routine human-use product; gray-market/compounded supply is not equivalent
Aliases
Geref GHRH(1-29) sermorelin acetate
Body areas
Pituitary GH axis liver IGF-1 axis bone and muscle via downstream GH signaling
Research availability
Older human literature and historical FDA approvals/discontinuation history
WADA relevance
Major athlete issue; prohibited as a GHRH analog
Well-established
Historically approved diagnostic/treatment products existed, but current consumer-market sermorelin does not sit on a current routine FDA-approved pathway.
Risks / limits
GH-axis adverse effects, contamination/quality concerns, athlete sanction risk, common misuse outside endocrine indications.
2024–2026 signal
FDA compounding discussions in 2024 highlighted that sermorelin had historical approval, but that does not validate current gray-market uses.
Hide details High Approved
Setmelanotide Severe early-onset hyperphagic obesity due to specific genetic disorders
FDA-approved human drug
Tap for details
Pathway / target
MC4 receptor agonist
Human availability
Yes — prescription use for specific rare disorders
Body areas
Hypothalamic appetite circuits melanocortin pathway adipose/metabolic system skin pigmentation
Research availability
Strong but rare-disease-specific human evidence
WADA relevance
Usually not a sports-doping issue
Well-established
Strong evidence in a narrow lane: certain genetically defined obesity syndromes, not general lifestyle obesity.
Risks / limits
Hyperpigmentation, GI effects, injection burden, specialized genetic/clinical screening required.
2024–2026 signal
A quiz should gate this behind formal diagnosis/genetic confirmation rather than broad weight-loss goals.
Hide details High Approved
Somatostatin analogs Acromegaly, hormone-secreting tumors, carcinoid syndrome, Cushing-specific contexts
FDA-approved human drug
Tap for details
Pathway / target
Somatostatin receptor agonists
Human availability
Yes — prescription/clinic use
Aliases
Octreotide lanreotide pasireotide; Sandostatin Somatuline Depot Signifor
Body areas
Pituitary pancreas gastrointestinal tract liver/gallbladder neuroendocrine tumor tissue
Research availability
Extensive specialty human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Well established, but the exact labeled use depends on the molecule: acromegaly, carcinoid/NET symptom control, and pasireotide for Cushing-related contexts.
Risks / limits
Gallstones, glucose dysregulation, GI effects, bradycardia/QT concerns depending on agent.
2024–2026 signal
Important specialty peptide class for disease-specific quizzes, not consumer optimization.
Hide details High Approved
Somatropin (recombinant human growth hormone) GH deficiency, pediatric growth disorders, body composition, recovery, anti-aging/bodybuilding
FDA-approved human drug
Tap for details
Pathway / target
Growth hormone receptor; hepatic IGF-1 axis
Human availability
Yes — prescription use for defined endocrine indications
Aliases
HGH 191AA rhGH Omnitrope Norditropin Nutropin
Body areas
Pituitary-liver IGF axis bone growth muscle adipose tissue glucose metabolism
Research availability
Extensive human trials + long clinical use
WADA relevance
Major athlete issue; prohibited in sport
Well-established
Established for GH deficiency and selected pediatric growth disorders; not a general wellness, anti-aging, or bodybuilding drug.
Risks / limits
Edema, arthralgia, insulin resistance, intracranial hypertension, pediatric orthopedic complications, athlete sanction risk.
2024–2026 signal
No major legality shift; remains tightly regulated and heavily misuse-prone in performance settings.
Hide details Moderate Educational
Survodutide Obesity plus MASH/fatty-liver interest
Investigational only
Tap for details
Pathway / target
GLP-1 / glucagon receptor agonist
Human availability
No — trial use only
Body areas
Brain appetite circuits liver fat/fibrosis pathways adipose tissue metabolic system
Research availability
Active phase 2/3 human research
WADA relevance
Usually not a sports-doping issue
Well-established
Meaningful mid-stage obesity and MASH data exist, but it remains investigational.
Risks / limits
GI effects and longer-term safety/efficacy still under study.
2024–2026 signal
Phase 2 MASH data were positive and phase 3 obesity/MASH programs continued in 2025–2026.
Hide details High Approved
Teduglutide Short bowel syndrome, intestinal adaptation
FDA-approved human drug
Tap for details
Pathway / target
GLP-2 analogue
Human availability
Yes — prescription use
Body areas
Intestinal mucosa gut absorptive surface biliary/pancreatic/GI tract
Research availability
Established human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Well established for reducing parenteral support needs in short bowel syndrome.
Risks / limits
GI obstruction, fluid overload, biliary/pancreatic monitoring, possible neoplasia surveillance issues.
2024–2026 signal
Highly effective in a niche GI-rehabilitation context; not a general wellness peptide.
Hide details High Approved
Teriparatide Osteoporosis, fracture risk, anabolic bone-building therapy
FDA-approved human drug
Tap for details
Pathway / target
PTH(1-34) analogue
Human availability
Yes — prescription use
Body areas
Bone remodeling system calcium metabolism skeleton
Research availability
Extensive human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Strong evidence for fracture risk reduction and bone formation in high-risk osteoporosis.
Risks / limits
Hypercalcemia, orthostasis, leg cramps; not a general 'performance' peptide.
2024–2026 signal
Key example of a peptide that is clearly effective, but only for a medically defined problem.
Hide details High Approved
Terlipressin Hepatorenal syndrome / advanced liver disease contexts
FDA-approved human drug
Tap for details
Pathway / target
Vasopressin analogue
Human availability
Yes — hospital/specialty use
Body areas
Systemic vasculature kidney perfusion portal/hepatic circulation
Research availability
Established human literature
WADA relevance
Usually not a sports-doping issue
Well-established
Well established only in a severe hepatology/inpatient setting.
Risks / limits
Respiratory failure, ischemic events, inpatient monitoring needs.
2024–2026 signal
This is clearly not a consumer peptide; include only if you want the quiz to be medically comprehensive.
Hide details Moderate to high Approved
Tesamorelin Visceral fat reduction in HIV-associated lipodystrophy; GH-axis discussions
FDA-approved human drug
Tap for details
Pathway / target
GHRH analogue / GH-axis peptide
Human availability
Yes — prescription use for a narrow indication
Body areas
Hypothalamus/pituitary GH axis liver visceral adipose tissue metabolic system
Research availability
Established human literature
WADA relevance
Often prohibited / TUE issues for athletes
Well-established
Well established only for reduction of excess abdominal fat in adults with HIV lipodystrophy; not a general anti-aging or body-composition peptide.
Risks / limits
IGF-1 elevation, edema, arthralgia, glucose intolerance, athlete anti-doping issues.
2024–2026 signal
Good example of a peptide that is legal for a specific indication but inappropriate for general body-recomposition marketing.
Hide details Low to moderate Educational
Thymosin alpha-1 Immune support, infection adjuncts, oncology adjunct claims
Not FDA-approved for human use
Tap for details
Pathway / target
Immune-modulating peptide
Human availability
No — not FDA-approved in the U.S.
Aliases
Ta1; thymalfasin in some literature
Body areas
Immune system infection/cancer adjunctive-immunology settings
Research availability
Human trials exist, but U.S. approval is absent
WADA relevance
Usually not a sports-doping issue
Well-established
There is real human research interest, but the molecule is not FDA-approved in the U.S. and should not be treated like a standard wellness peptide.
Risks / limits
FDA says safety-related information is inadequate for proposed compounded drug use.
2024–2026 signal
Useful to classify as 'under study abroad / not approved here' rather than lumping it with pure fantasy peptides.
Hide details Very low Educational
Thymosin beta-4 / TB-500 family Recovery, tendon/ligament healing, soft-tissue repair
Not FDA-approved for human use
Tap for details
Pathway / target
Experimental repair / wound-healing signaling
Human availability
No — do not market for human use
Aliases
TB-500; thymosin beta-4 fragment LKKTETQ
Body areas
Skin/wound bed cornea tendon/ligament muscle-repair signaling
Research availability
Some human research; marketed use far outruns evidence
WADA relevance
Often prohibited / high-risk for athletes
Well-established
There is some legitimate research history around thymosin beta-4 biology, but the marketed TB-500 narrative greatly outruns the evidence.
Risks / limits
FDA flags the fragment as lacking human exposure data; athlete anti-doping risk is substantial for TB-500-type products.
2024–2026 signal
Use a hard caution label in any quiz because the market narrative is much stronger than the human evidence.
Hide details High Approved
Tirzepatide Obesity, type 2 diabetes, sleep apnea, aggressive weight-loss interest
FDA-approved human drug
Tap for details
Pathway / target
Dual GIP/GLP-1 receptor agonist
Human availability
Yes — prescription use
Body areas
Brain appetite circuits pancreas stomach liver adipose tissue cardiovascular system upper airway/OSA via weight reduction
Research availability
Extensive human trials + post-marketing use
WADA relevance
Usually not a sports-doping issue
Well-established
Strong evidence for weight loss and glycemic control; FDA-approved for obesity and type 2 diabetes, with an OSA indication in adults with obesity.
Risks / limits
GI adverse effects, gallbladder disease, pancreatitis warning, kidney injury warning, retinopathy caution in diabetes, thyroid C-cell tumor boxed warning.
2024–2026 signal
2024: first FDA-approved medication for OSA in adults with obesity; 2025 trial data showed greater weight loss than semaglutide in a head-to-head obesity study and benefit in HFpEF with obesity.
Hide details Low to moderate Educational
VIP / Aviptadil Respiratory failure, inflammation, erectile-dysfunction history, “healing” claims
Investigational only
Tap for details
Pathway / target
VPAC receptor agonist
Human availability
No — no FDA-approved human-use product identified
Aliases
VIP aviptadil RLF-100
Body areas
Lung epithelium pulmonary vasculature smooth muscle neuroimmune signaling
Research availability
Human trials in respiratory failure and other niche settings
WADA relevance
Usually not a sports-doping issue
Well-established
Synthetic VIP has been studied in humans, but a major randomized COVID respiratory-failure trial did not show significant clinical benefit versus placebo.
Risks / limits
No FDA-approved pathway, mixed efficacy data, specialized inpatient trial context unlike gray-market marketing.
2024–2026 signal
Useful as an example of a peptide with real trials but no routine approved U.S. use.
Hide details Moderate Educational
VK2735 Obesity and diabetes pipeline interest
Investigational only
Tap for details
Pathway / target
Dual GIP/GLP-1 receptor agonist
Human availability
No — trial use only
Aliases
Viking dual incretin candidate
Body areas
Brain appetite circuits pancreas stomach liver adipose tissue
Research availability
Active phase 2/3 human research
WADA relevance
Usually not a sports-doping issue
Well-established
Human trial signals are promising, but evidence is still development-stage and not approval-grade yet.
Risks / limits
GI effects and long-term safety still under study.
2024–2026 signal
Phase 3 obesity studies were initiated by 2025–2026.
Hide details High Approved
Vosoritide Achondroplasia growth management
FDA-approved human drug
Tap for details
Pathway / target
C-type natriuretic peptide analogue
Human availability
Yes — prescription/specialty pediatric use
Body areas
Growth plate cartilage endochondral bone growth vascular tone
Research availability
Strong human evidence in labeled population
WADA relevance
Usually not a sports-doping issue
Well-established
Well established for children with achondroplasia and open growth plates.
Risks / limits
Hypotension, injection reactions, age/growth-plate limits.
2024–2026 signal
Highly specific peptide with strong evidence but very narrow routing.
Hide details High Approved
Ziconotide Severe refractory chronic pain via intrathecal pump
FDA-approved human drug
Tap for details
Pathway / target
N-type calcium channel blocker peptide
Human availability
Yes — specialist intrathecal use
Body areas
Spinal cord / CNS pain pathways
Research availability
Strong niche human evidence
WADA relevance
Usually not a sports-doping issue
Well-established
Effective in carefully selected severe pain cases when delivered intrathecally.
Risks / limits
Serious neuropsychiatric adverse effects, device/procedural complexity, specialist-only use.
2024–2026 signal
Strong evidence, but extremely narrow and high-risk operational context.
Hide details